These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 27464720)

  • 21. Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system.
    Calcagno A; Di Perri G; Bonora S
    Clin Pharmacokinet; 2014 Oct; 53(10):891-906. PubMed ID: 25200312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Applications of nanotechnology in drug delivery to the central nervous system.
    Saeedi M; Eslamifar M; Khezri K; Dizaj SM
    Biomed Pharmacother; 2019 Mar; 111():666-675. PubMed ID: 30611991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting anti-HIV drugs to the CNS.
    Rao KS; Ghorpade A; Labhasetwar V
    Expert Opin Drug Deliv; 2009 Aug; 6(8):771-84. PubMed ID: 19566446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential Tools for Eradicating HIV Reservoirs in the Brain: Development of Trojan Horse Prodrugs for the Inhibition of P-Glycoprotein with Anti-HIV-1 Activity.
    Agrawal N; Rowe J; Lan J; Yu Q; Hrycyna CA; Chmielewski J
    J Med Chem; 2020 Mar; 63(5):2131-2138. PubMed ID: 31505928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physical and Metabolic Integrity of the Blood-Brain Barrier in HIV Infection: A Special Focus on Intercellular Junctions, Influx and Efflux Transporters and Metabolizing Enzymes.
    Shawahna R
    Curr Drug Metab; 2015; 16(2):105-23. PubMed ID: 26179607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of CNS Viral Seeding by HIV
    Veenstra M; León-Rivera R; Li M; Gama L; Clements JE; Berman JW
    mBio; 2017 Oct; 8(5):. PubMed ID: 29066542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroprotective and anti-human immunodeficiency virus activity of minocycline.
    Zink MC; Uhrlaub J; DeWitt J; Voelker T; Bullock B; Mankowski J; Tarwater P; Clements J; Barber S
    JAMA; 2005 Apr; 293(16):2003-11. PubMed ID: 15855434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current understanding of HIV-associated neurocognitive disorders pathogenesis.
    Gannon P; Khan MZ; Kolson DL
    Curr Opin Neurol; 2011 Jun; 24(3):275-83. PubMed ID: 21467932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanoparticle-mediated targeted delivery of antiretrovirals to the brain.
    Mahajan SD; Law WC; Aalinkeel R; Reynolds J; Nair BB; Yong KT; Roy I; Prasad PN; Schwartz SA
    Methods Enzymol; 2012; 509():41-60. PubMed ID: 22568900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Could differential virological characteristics account for ongoing viral replication and insidious damage of the brain during HIV 1 infection of the central nervous system?
    Vissers M; Stelma FF; Koopmans PP
    J Clin Virol; 2010 Dec; 49(4):231-8. PubMed ID: 20833583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-TAT protein upregulates expression of multidrug resistance protein 1 in the blood-brain barrier.
    Hayashi K; Pu H; Andras IE; Eum SY; Yamauchi A; Hennig B; Toborek M
    J Cereb Blood Flow Metab; 2006 Aug; 26(8):1052-65. PubMed ID: 16395283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?
    Sanchez-Covarrubias L; Slosky LM; Thompson BJ; Davis TP; Ronaldson PT
    Curr Pharm Des; 2014; 20(10):1422-49. PubMed ID: 23789948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-HIV Activity of Cucurbitacin-D against Cigarette Smoke Condensate-Induced HIV Replication in the U1 Macrophages.
    Kodidela S; Sinha N; Kumar A; Kumar S
    Viruses; 2021 May; 13(6):. PubMed ID: 34072078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical implications of HIV-1 drug resistance in the neurological compartment.
    Antinori A; Cingolani A; Giancola ML; Forbici F; De Luca A; Perno CF
    Scand J Infect Dis Suppl; 2003; 106():41-4. PubMed ID: 15000582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamic of CSF and serum biomarkers in HIV-1 subtype C encephalitis with CNS genetic compartmentalization-case study.
    de Almeida SM; Rotta I; Ribeiro CE; Oliveira MF; Chaillon A; de Pereira AP; Cunha AP; Zonta M; Bents JF; Raboni SM; Smith D; Letendre S; Ellis RJ
    J Neurovirol; 2017 Jun; 23(3):460-473. PubMed ID: 28247269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How much do antiretroviral drugs penetrate into the central nervous system?
    Ene L; Duiculescu D; Ruta SM
    J Med Life; 2011 Nov; 4(4):432-9. PubMed ID: 22514580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis E virus infects brain microvascular endothelial cells, crosses the blood-brain barrier, and invades the central nervous system.
    Tian D; Li W; Heffron CL; Wang B; Mahsoub HM; Sooryanarain H; Hassebroek AM; Clark-Deener S; LeRoith T; Meng XJ
    Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2201862119. PubMed ID: 35671427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration?
    Koopmans PP; Ellis R; Best BM; Letendre S
    Neth J Med; 2009 Jun; 67(6):206-11. PubMed ID: 19749389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple Faceted Roles of Cocaine in Potentiation of HAND.
    Cai Y; Yang L; Callen S; Buch S
    Curr HIV Res; 2016; 14(5):412-416. PubMed ID: 27009095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.